Please assess the completion status of the following clinical trial:

Trial Title: MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (Recipient):~* Meets ONE of the following disease criteria:~  1. Primary AML induction failure: no CR after 2 or more induction attempts~ 2. Relapsed AML or Secondary AML (from MDS or treatment related): not in CR after 1 or more cycles of standard re-induction therapy~ 3. AML relapsed \> 2 months after transplant: No re-induction required, and no more than 1 re-induction cycle is allowed.~ 4. Relapsed AML for patients \> 60 years of age the 1 cycle of standard chemotherapy is not required if either of the following criteria is met:~     * Relapse within 6 months of last chemotherapy~    * BM blast count \< 30% within 10 days of starting protocol therapy~* Available related HLA-haploidentical donor (aged 14 to 75 years) by at least Class I serologic typing at the A\&B locus~* Karnofsky Performance Status ≥ 60%~* Patients must have adequate organ within 14 days (28 days for pulmonary and cardiac) of study registration~* Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications).~* Agrees to use contraception prior to study entry and for the duration of study participation.~Exclusion Criteria (Recipient):~* Bi-phenotypic acute leukemia.~* Transplant \< 60 days prior to study enrollment.~* Active autoimmune disease.~* History of severe asthma~* Uncontrolled intercurrent illness~* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been evaluated with bronchoscopy~* Pleural effusion large enough to be detectable on chest x-ray.~* Pregnant women~* History of HIV, active or chronic hepatitis B, hepatitis C or HTLV-I infection~* Known hypersensitivity to any of the study agents used~* Received investigational drugs within the 14 days of study registration.~* Known active CNS involvement.~Criteria For Initial Donor Selection:~* Related donors (sibling, parent, offspring, parent or offspring of an HLA identical sibling).~* 14-75 years of age.~* At least 40 kilogram body weight.~* In general good health as determined by the evaluating medical provider.~* HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A\&B locus.~* Not pregnant.~* Able and willing to undergo apheresis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Preparative Regimen and SubQ rHuIL-15 (Type: EXPERIMENTAL): Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).